GlassScriptPhysician profile
Emily Bogert
NPI 1619682945
$4,988.64
in general payments reported to CMS, 2019-2025
22 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.91 · 2023: $1,669 · 2024: $1,875 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,383 · Education: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,383.23 |
| Education | $543.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,535.63 | 2023-2025 | |
| Incyte Corporation | $502.38 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $496.50 | 2023-2025 | Tremfya |
| Medtronic, INC. | $463.50 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $345.34 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $330.85 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Ucb, INC. | $284.36 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $279.20 | 2023-2025 | |
| Genzyme Corporation | $137.33 | 2023-2024 | |
| Lilly USA, LLC | $102.64 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $86.76 | 2023-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.52 | 2023-2024 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.87 | 2023-2025 | Siliq, Duobrii, Targretin |
| Galderma Laboratories, L.P. | $50.02 | 2024 | |
| Leo Pharma INC. | $48.45 | 2022-2023 | Adbry |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $45.68 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $40.27 | 2024 | Zoryve |
| Bolton Medical INC | $22.32 | 2025 | Gelweave, Thoraflex Hybrid |
| Mimedx Group, INC. | $20.62 | 2025 | |
| Genentech USA, INC. | $17.42 | 2023 | Erivedge |
| Pfizer INC. | $15.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2023 | Sprycel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Bogert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.